Analyst Cuts Arena (ARNA) to Sell as Lorcaserin 'Cancer Risk Unlikely to be Ruled Out'
Tweet Send to a Friend
An analyst at Summer Street Research downgraded shares of Arena Pharma (Nasdaq: ARNA) all the way from Buy to Sell ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
